Jonathan McNeill - Jul 5, 2022 Form 4 Insider Report for Dyne Therapeutics, Inc. (DYN)

Role: Senior Vice President of Business Development
Signature: /s/ Richard Scalzo, Attorney-in-Fact
Stock symbol: DYN
Transactions as of: Jul 5, 2022
Transactions value $: $0
Form type: 4
Date filed: 7/6/2022, 06:21 PM
Previous filing: Jun 15, 2022
Next filing: Sep 15, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DYN	Stock Option (right to buy)	Award	$0	+21.7K		$0.00	21.7K	Jul 5, 2022	Common Stock	21.7K	$5.54	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option was granted on July 31, 2020, with 100% of the option to vest upon the clearance date of an Investigational New Drug (IND) application submitted to the U.S. Food and Drug Administration (FDA) by the Company with respect to one of its product candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined that the performance condition had been achieved.

Content

The option was granted on July 31, 2020, with 100% of the option to vest upon the clearance date of an Investigational New Drug (IND) application submitted to the U.S. Food and Drug Administration (FDA) by the Company with respect to one of its product candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined that the performance condition had been achieved.

Remarks:

Senior Vice President of Business Development